GLK-321 low dose BID
Phase 2Small molecule
GLK-321 low dose BID is one of 21 small molecule programs targeting Blepharitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Blepharitis
#DrugCompanyPhaseTrials
1E-Mycin
AAzurity Pharmaceuticals
Approved
Elidel
BBausch Health Americas, Inc.
Approved
Flagyl
DDePuy Orthopaedics
Approved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Levaquin
WWim Janssens
Approved
Tobrex
VViatris Specialty LLC
Approved
Lotemax
PPharmos
Approved
Decadron
AAspen Global Incorporated
Phase 3
Flovent
GSKPhase 2
Azasite
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GLK-321 low dose BID. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGlaukos Corporation